SLC5A2 and kidney disorder: This guideline’s aims were to: (i) provide guidance on use of SGLT-2 inhibitors in people with CKD, focusing on the potential to modify risk of kidney disease progression; and (ii) support safe implementation of SGLT-2 inhibitors into clinical practice in people with CKD.